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 In 20% to 30% of patients with follicular lymphoma (FL), the disease shows an aggressive behavior.
 Novel biomarkers are available in FL each with a different ability to identify high-risk patients.














| 82Introduction heterogeneity of high-risk FL which is so far defined byFor many years, risk in follicular lymphoma (FL) has been defined
with conventional clinical prognostic factors and indexes with the
follicular lymphoma international prognostic indexes (FLIPI and
FLIPI2) being the most frequently used scores.1,2 None of these
indexes, however, has ever been able to unequivocally identify
high-risk patients.
Current state of the art
Recently, Casulo et al
∗3 correlated the concept of high-risk FL with
time to progression. The authors showed that patients with high
tumor burden FL who progress or relapse within 24 months
(POD24) after immunochemotherapy (here: Cyclophosphamide,
Doxorubicin, Vincristine, Prednisone [CHOP] with the anti-CD20
antibodyRituximab [R]) had a significantly shorter overall survival
(OS) compared with patients without POD24. These findings were
recently validated in independent FL patient cohorts and with
immunochemotherapy regimens different from R-CHOP.4,5
POD24 is an important step toward a better understanding of
FL; however, patients would rather benefit from a better risk
stratification closer to FL diagnosis, thereby allowing the
development of risk-modifying approaches. In that respect, theing/support: None.
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| Educational Updates in Hematology Book | 2019; 3(S2)refractoriness and transformation needs to be better understood.
These patients’ higher risk of dying is mainly caused by
lymphoma6 and might be driven not only by a more aggressive
biology of FL but also by refractoriness to immunochemotherapy
and by a higher risk of transformation. Indeed, the combination of
different dimensions contributes to increasing the risk in FL. In
this context, novel tools have recently been studied to identify
high-risk FL, with most of the available data coming from the
analysis of molecular, pathologic, and metabolic features of the
disease.Baseline biomarkers
A number of studies have found associations between several
pathologic features such as histologic grading, proliferation index,
and microenvironment in diagnostic FL biopsies and varying
degrees of disease aggressiveness, but have not confirmed these
features as reliable prognosticators in the era of immunochemo-
therapy.7 Advanced noninvasive methods for the detection of cell-
free DNA in general and more specifically of circulating tumor
DNA are underway, to determine the tumor load which could be
used for pretherapeutic risk assessment.8
Two attempts have been made to integrate clinical prognostic
factors with molecular biomarkers: Pastore et al
∗9 integrated the
mutational status of 7 genes recurrently mutated in FL in the
context of the FLIPI backbone and Huet et al10 used gene
expression analysis to identify a 23-gene predictor model. Both the
m7-FLIPI and the 23-gene model identified a high-risk group of
28% and of 21% to 35% of patients, respectively, who had a
shorter PFS. A simplified version of m7-FLIPI was also validated
allowing to predict the risk of POD24 in up to 80% of high-risk
patients.11
Finally, since 18F-fluordesoxyglucose (FDG) avidity was
confirmed in the majority of FL, the prognostic value of
quantitative parameters obtained from baseline FDG-PET/
computed tomography has been analyzed. Of these parameters,
standardized uptake value (SUV) has been shown to be a good
tool to identify areas at higher risk of histologic transformation tumor-free DNA holds promises to a deeper understanding of FL
Table 1
Summary of Prognostic Factors Used to Identify HRFL Patients and Correlation With POD24
Score/Factor HRFL Def. HRFL% Time, y PFS, % OS, % POD24% in HRFL Ref.
Baseline
FLIPI 3–5 RF 28 5 — 53 55 1,
∗3
FLIPI2 3–5 RF 27 5 19 77 — 2
TMTV >510 cm3 29 5 33 85 41 12
m7-FLIPI Calculated 22–28 5 38 (FFS) 42–65 43–61
∗9
POD24-PI Calculated 36–42 5 36–50 (FFS) 48–71 61–78 11
23-Gene model Calculated 35 5 26 — 38 10
Postinduction
EOI PET DS 4–5 17 4 23 87 —
∗14
EOI PET DS 4–5 12 2.5 54 84 — 16
MR t (14;18) >10 e4 DNA copies @12 mo 20–50 3 41 — — 13
Combined models
TMTV + FLIPI2 >510 cm3 and 3–5 RF 14 5 20 87 — 12
EOI PET + EOI-MR DS 4–5 or > 10 e4 DNA Copies @EOI 16 2.5 69 — — 19
TMTV + EOI PET >510 cm3 and DS 4–5 8 5 23 83 — 17
DS = Deauville score, EOI = end of induction, FFS = failure-free survival, FLIPI = follicular lymphoma international prognostic index, HRFL = high-risk follicular lymphoma, MR = molecular response, OS = overall
survival, PET = positron emission tomography, PFS = progression-free survival, POD24 = progression of disease within 24 months from treatment start, RF = risk factors, TMTV = total metabolic tumor volume.
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importantly, in a recent study by Meignan et al,12 baseline total
metabolic tumor volume (TMTV), defined as the sum of the
volumes of sites with an SUV value above a significant threshold,
has been confirmed as the strongest pretreatment prognostic
factor, able to identify a third of patients at higher risk of
progression and of dying from FL, independently of FLIPI and
FLIPI2 (Table 1).
The above-mentioned molecular and metabolic biomarkers
represent new tools to identify high-risk patients at diagnosis and
might be used to support biology guided therapies (ie, EZH2
inhibitors). However, they both show limitations in their
reproducibility and require further investigations in the
context of prospective studies and in different subgroups of FL
patients (ie, low tumor burden cases and patients treated with
new drugs).
Postinduction prognostic tools
Response to therapy assessed either with FDG-PET or with
highly sensitive molecular techniques that are able to measure
cell-free DNA or to determine low levels of the t(14;18)
chromosomal translocation (minimal residual disease [MRD])
have recently been suggested as useful prognostic tools.13–15
Trotman et al recently reported the results of the largest study ever
conducted, to investigate the prognostic role of metabolic
response in more than 500 patients with treatment-naïve
advanced-stage FL enrolled in the GALLIUM trial. The authors
were able to confirm that metabolic response to induction
immunochemotherapy is prognostic both for PFS and OS, and
that Lugano response criteria are accurate and reproducible in FL.
More importantly, this study showed that metabolic response is
associated with prognosis in nearly all advanced-stage FL
patients, including those who receiving maintenance therapy
and those who treated with the new generation anti-CD20
monoclonal antibody (ie, obinutuzumab) and different chemo-
therapy backbones.16
Future perspective
In summary, several biomarkers and prognostic factors are
currently available to identify a subgroup of approximately 20%
to 30% of patients with FL whose lymphoma show an aggressive
clinical behavior. The use of novel techniques tomeasure cell-free orheterogeneity, and for a better monitoring of response to
treatment, hopefully leading to the identification of novel
biomarkers.8 Each available biomarker has a different ability
to predict outcome and likely describes different features of the
higher individual risk. Since none of the prognostic factors
identified so far is currently available to accurately identify high-
risk FL and applies to the clinical and biological heterogeneity of
FL, a reasonable strategy might be to combine available factors.
Indeed, recent results showed that baseline and postinduction
factors can be successfully combined (ie, TMTV + FLIPI2, TMTV
+ metabolic response, metabolic response + molecular
response).12,17,
∗18,19,20 Clinical trials are underway that investi-
gate the efficacy of a response-adapted approach, based on the use
of novel prognostic biomarkers including FDG-PET and/or
MRD, aiming to tailor the postinduction maintenance phase of
therapy to the quality of response (NCT02063685 and EudraCT
2016-004010-10).References
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